Introduction to DNA vaccines - Las Vegas

Vaccine

Volumn 28, Issue 8, 2010, Pages 1893-1896

  Weiner, David B ^a   Sardesai, Niranjan Y ^b   Schmaljohn, Connie ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VGX Pharmaceuticals Inc   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GENE PRODUCT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LENTIVIRUS VECTOR; LIFETIDE; LIPOSOME; PLASMID DNA; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

CHEMICAL MODIFICATION; CLINICAL TRIAL; CODON; CONTROLLED DRUG RELEASE; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DNA PURIFICATION; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; ELECTROPORATION; GENE EXPRESSION; GENE GUN; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; INFECTIOUS HEMATOPOIETIC NECROSIS VIRUS; MAMMAL CELL; NANOTECHNOLOGY; NEOPLASM; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VACCINE PRODUCTION; WEST NILE FLAVIVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ELECTROPORATION; HUMANS; IMMUNIZATION, SECONDARY; VACCINES, DNA;

EID: 76949088838     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.052     Document Type: Editorial

References (0)